Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
IRVINE, Calif., May 09, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE:IMUC). Investors who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 30, 2017 lead plaintiff motion deadline.
If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 were going well and the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell materially, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
